Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

• Status: Active, not recruiting
• Trial end date: 2024-01-01

Summary

The aim of this study is to evaluate if standard chemoimmunotherapy (FCR, BR) in frontline treatment of physically fit CLL patients without del17p or TP 53 mutation can be replaced by combinations of targeted drugs (Venetoclax, Ibrutinib) with anti-CD20-antibodies (Rituximab, Obinutuzumab), which may induce extremely long lasting remissions.

• Phase: Phase 3

Details

• Lead Sponsor: German CLL Study Group
• Collaborators: AbbVie; Cancer Trials Ireland; Hoffmann-La Roche; Israeli CLL Study Group; Janssen-Cilag Ltd.; Nordic CLL Study Group (NCLLSG); Stichting Hemato-Oncologie voor Volwassenen Nederland; Swiss Group for Clinical Cancer Research
• Treatments: Bendamustine Hydrochloride; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Obinutuzumab; Rituximab; Venetoclax